Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Activaero inhales €10.7m in series A

This article was originally published in Clinica

Executive Summary

Activaero, a German specialist in inhaled drug delivery technologies, has raised €10.7m ($15.8m) in its first round of venture financing. The series A round was led by BioMedPartners, and included VI Partners, Abalis Finance and Vesalius Biocapital I SICAR. The funds will go towards new product development and commercialisation. Gemünden-based Activaero's products – it currently has two on the market, the Akita and the Watchhaler – incorporate its controlled breathing technology that allows for more precise and patient-tailored delivery of inhaled therapeutics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel